EUVIMEDEUVIMED entdecken
Crossref

Harnessing minimal residual disease for precision medicine in locally advanced gastric cancer

Xiao-Wei Guo, Xin-Xin Xu, Bing-Jie Deng, Guang-Fu Zhou, Qian Zhou, Xiao-Xin Gao, Cheng-Zhou Du, Zhi Qiao, Hong-Tao Li

World Journal of Clinical Oncology · 24.07.2026 · 17 (7)

DOI: 10.5306/wjco.121993 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Clinical Oncology, online erschienen am 24.07.2026. Verfasst von Xiao-Wei Guo und 8 weiteren Autor:innen. Die Arbeit nennt 71 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric cancer remains a major cause of cancer-related mortality, and recurrence after radical-intent therapy is a central obstacle in locally advanced gastric cancer (LAGC). Minimal residual disease (MRD) refers to occult residual tumor burden that cannot be detected by conventional imaging or routine laboratory tests but may later drive recurrence. Circulating tumor DNA (ctDNA), a tumor-derived fraction of circulating cell-free DNA that is mainly released into the bloodstream during tumor-cell apoptosis and necrosis, has emerged as a promising non-invasive biomarker for MRD assessment. In LAGC, ctDNA-MRD detection may support recurrence-risk stratification, postoperative surveillance, molecular response assessment after neoadjuvant therapy, and exploratory evaluation of treatment efficacy, including immunotherapy. However, current evidence should be interpreted cautiously. Most available studies are observational, include modest cohorts, use heterogeneous assay platforms and sampling schedules, and apply non-uniform thresholds for MRD positivity. Therefore, the best-supported role of ctDNA-MRD in LAGC is currently prognostic rather than definitively predictive or treatment-directing. This narrative review summarizes the biological basis of ctDNA, major polymerase chain reaction- and next-generation sequencing-based detection strategies, representative clinical evidence in LAGC, and the main barriers to clinical implementation. CtDNA-MRD assessment has substantial potential to refine precision management in LAGC, but routine treatment modification based solely on ctDNA status requires prospective, interventional validation and standardized analytical workflows.

Zitieren

APA

Guo, X., Xu, X., Deng, B., Zhou, G., Zhou, Q., Gao, X., Du, C., Qiao, Z., & Li, H. (2026). Harnessing minimal residual disease for precision medicine in locally advanced gastric cancer. World Journal of Clinical Oncology, 17(7). https://doi.org/10.5306/wjco.121993

Vancouver

Guo X, Xu X, Deng B, Zhou G, Zhou Q, Gao X, et al. Harnessing minimal residual disease for precision medicine in locally advanced gastric cancer. World Journal of Clinical Oncology. 2026;17(7). doi:10.5306/wjco.121993

BibTeX
@article{Guo2026,
  author = {Guo, Xiao-Wei and Xu, Xin-Xin and Deng, Bing-Jie and Zhou, Guang-Fu and Zhou, Qian and Gao, Xiao-Xin and Du, Cheng-Zhou and Qiao, Zhi and Li, Hong-Tao},
  title = {Harnessing minimal residual disease for precision medicine in locally advanced gastric cancer},
  journal = {World Journal of Clinical Oncology},
  year = {2026},
  volume = {17},
  number = {7},
  doi = {10.5306/wjco.121993}
}
Kostenlos starten →